Andrea S. Lukes

PURPOSE: Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometrios…

Purpose: Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometrios…

Andrea S Lukes,1 Roberta Venturella,2 Krzysztof Dynowski,3 Rachel B Wagman,4 Julie S Perry,4 Yi Zhong,5 Viatcheslav G Rakov,6 Sylvia Mechsner,7 Neil P Johnson81Carolina Woman’s Research and Wellness Center, Durham, NC, USA; 2Department of C…

OBJECTIVE: In the LIBERTY 1 and LIBERTY 2 placebo-controlled trials, once-daily relugolix combination therapy reduced menstrual blood loss volume and pain in women with heavy menstrual bleeding associated with uterine leiomyomas and was wel…

OBJECTIVE: The prospective SONATA pivotal Investigational Device Exemption (IDE) trial was performed in the United States (US) and Mexico to examine the safety and effectiveness of transcervical fibroid ablation (TFA) in the treatment of sy…

BACKGROUND: Adenomyosis is a poorly understood, benign disease of the uterus. OBJECTIVE: In this study, patient interviews were conducted to characterize the symptoms and impact of adenomyosis. METHODS: This was a cross-sectional study in…

Carolina Women's Research and Wellness Center, Durham, North Carolina Financial Disclosure The author did not report any potential conflicts of interest. Dr. Lukes is a current PI on an AEGEA clinical trial for endometrial ablations, and ga…

BACKGROUND: Women with abnormal uterine bleeding (AUB) may be treated surgically with hysterectomy or global endometrial ablation (GEA), an outpatient procedure. We compared the costs and clinical outcomes of these surgical procedures for A…

Leiomyomata uteri remain a common gynecologic problem, associated with a significant clinical and economic burden of illness. Despite a variety of currently available interventions for uterine fibroids, there remains an unmet clinical need …

The challenge for all endometrial ablation technologies is the unique and impressive ability of the endometrium to regenerate. The endometrium is predominantly an endocrine organ that responds to a sequence of orchestrated hormonal signals …

Introduction: Menorrhagia is a common health problem affecting ∼5-10% of women. The optimal management of menorrhagia among women with abnormal laboratory hemostasis is uncertain. The goal of this study was to determine the effect of intran…